Organovo Holdings, Inc. (NASDAQ:ONVO), a biotech firm specializing in biological products with a current market capitalization of just $5.92 million, announced on Thursday that it has received a ...

Organovo Holdings, Inc. (NASDAQ:ONVO), a biotech firm specializing in biological products with a current market capitalization of just $5.92 million, announced on Thursday that it has received a ...

Organovo Holdings, Inc. (Nasdaq:ONVO), a clinical stage biotechnology company focused on developing novel treatment approaches in inflammatory bowel disease (IBD) including ulcerative colitis, today ...

SAN DIEGO, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq:ONVO), a clinical stage biotechnology company focused on developing novel treatment approaches in inflammatory bowel ...

(RTTNews) - Organovo Holdings, Inc. (ONVO), a clinical-stage biotech firm focused on advancing innovative treatments for inflammatory bowel disease, on Monday announced the appointment of Norman ...

SAN DIEGO, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq:ONVO), a clinical stage biotechnology company focused on developing novel treatment approaches in inflammatory bowel ...

Norm has also worked on several recent M&A deals in the biotech industry. “We are excited to welcome Norm to the Organovo team,” said Keith Murphy, Executive Chairman. “With his extensive experience, ...

Shares of NASDAQ ONVO opened at $0.37 on Friday. Organovo has a 12 month low of $0.32 and a 12 month high of $1.74. The company has a market cap of $5.69 million, a price-to-earnings ratio of -0. ...